LEXICON PHARMACEUTICALS, INC. Repayments of Debt
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Repayments of Debt of $59.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. repayments of debt for the quarter ending 2026-06-30 was $54.26M, a 20.58% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. repayments of debt for the quarter ending 2026-03-31 was $5.00M.
- LEXICON PHARMACEUTICALS, INC. repayments of debt for the quarter ending 2025-12-31 was $3.00M.
- LEXICON PHARMACEUTICALS, INC. repayments of debt for the quarter ending 2025-09-30 was $0.00.
- LEXICON PHARMACEUTICALS, INC. repayments of debt for fiscal 2025 was $48.00M.
- LEXICON PHARMACEUTICALS, INC. repayments of debt for fiscal 2024 was $0.00.
- LEXICON PHARMACEUTICALS, INC. repayments of debt for fiscal 2023 was $0.00.
| Period end | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $54.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $59.26M 10-Q · filed 2026-08-06 | $62.26M derived: sum of 3 quarters · filed 2026-08-06 | $62.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.00M 10-Q · filed 2026-05-07 | $8.00M derived: sum of 2 quarters · filed 2026-05-07 | $8.00M derived: sum of 3 quarters · filed 2026-05-07 | $53.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.00M derived: sum of 2 quarters · filed 2026-03-05 | $48.00M derived: sum of 3 quarters · filed 2026-08-06 | $48.00M 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $45.00M derived: sum of 2 quarters · filed 2026-08-06 | $45.00M 10-Q · filed 2025-11-06 | $45.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $45.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $45.00M 10-Q · filed 2026-08-06 | $45.00M derived: sum of 3 quarters · filed 2026-08-06 | $45.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |